Ophthalmic specialization
Category depth across retina, cornea, glaucoma, and rare ophthalmic disease — informed by precedent trials, imaging standards, and specialty care pathways, not generalist life-sciences consulting.
About
Vision. Science.
Impact.
A global ophthalmic biotech advisory firm — scientific rigor, regulatory depth, and disciplined execution for sponsors, investors, and institutional partners.
Why sponsors choose us
Ophthalmic advisory built for institutional sponsors
Senior advisors who align development, regulatory, access, and commercialization — with governance-ready deliverables.
Global regulatory expertise
FDA, EMA, and selected regional pathways mapped with ophthalmic-specific precedents — briefing strategy, endpoint acceptability, and combination-product considerations included from the outset.
Science and commercial alignment
Mechanism, clinical evidence, and development constraints translated into positioning, payer-relevant narratives, and partner-ready materials that internal teams can execute.
Disciplined execution
Senior advisors deliver governance-ready outputs on defined timelines — integrated with your R&D, regulatory, and commercial leads rather than parallel workstreams.
Senior advisory model
Direct access to experienced operators; clear accountability, concise governance, and materials suitable for boards, investors, and agency interactions.
Patient-centered outcomes
Recommendations anchored to functional vision endpoints, treatment burden, and real-world implications for patients and treating specialists.
Evidence-led advisory for ophthalmic development, regulatory strategy, and commercialization.
Senior consultants aligned to sponsor governance, agency dialogue, and patient-relevant endpoints.
Scientific expertise
Depth across
the ophthalmic lifecycle
Integrated advisory from translational science through regulatory dialogue, access planning, and launch readiness.
Retina therapeutics
Endpoint hierarchies, imaging governance, and trial operations for diabetic retinopathy, AMD, and retinal vein occlusion programs.
Gene therapy
Indication sequencing, long-term follow-up planning, and access implications for subretinal and intravitreal gene-based therapies.
Clinical development
Protocol design, enrollment risk mitigation, and CRO oversight for multi-regional ophthalmic trials.
Commercialization readiness
Launch governance, medical affairs alignment, and lifecycle planning for specialty-administered ophthalmic therapies.
Global reach
Global advisory coverage
across major markets
United States, Europe, MENA, APAC, and select emerging markets — supported through established CRO, regulatory, and commercial partners with ophthalmic depth.
United StatesEuropeMENAAPACEmerging Markets
Engagement process
Structured engagement from assessment through launch
A defined sequence aligning science, regulation, access, and commercialization — scaled to program stage, modality, and governance requirements.
1
Strategic assessment
Structured review of program stage, competitive context, and highest-leverage decisions across development, evidence, and positioning.
Governance-ready deliverables
2
Regulatory alignment
Pathway mapping, agency interaction planning, and endpoint strategy grounded in ophthalmic regulatory precedent.
Governance-ready deliverables
3
Clinical planning
Trial architecture, imaging and biomarker strategy, and operational planning to keep studies executable and defensible.
Governance-ready deliverables
4
Market access strategy
Evidence plans and value narratives aligned to US payer policy and major HTA requirements.
Governance-ready deliverables
5
Commercialization support
Launch readiness, medical affairs coordination, and lifecycle planning for first and follow-on indications.
Governance-ready deliverables
Built to integrate with your team
We embed alongside R&D, regulatory, medical, and commercial leadership — providing senior direction, crisp governance, and deliverables that keep your program moving.
Leadership & advisory
Senior advisors with ophthalmic operating experience
Direct access to leaders across clinical development, global regulation, and commercialization — accountable for decisions, not slide volume.
Senior Ophthalmic Advisor
Clinical & Translational Strategy
25+ years
Retina development, imaging endpoints, and evidence generation for pivotal trials and label strategy
Headshots available upon request. Advisor identities can be shared under NDA.
Regulatory Lead
Global Pathway & Agency Strategy
20+ years
FDA and EMA interactions, briefing packages, and combination-product pathways in ophthalmology
Headshots available upon request. Advisor identities can be shared under NDA.
Commercial & Access Partner
Value, Access, and Launch Readiness
18+ years
HEOR framing, payer engagement, launch governance, and post-approval lifecycle planning
Headshots available upon request. Advisor identities can be shared under NDA.
Need specialist support beyond the core team? We activate a curated network of ophthalmology KOLs, imaging and biomarker partners, HEOR experts, and regional regulatory specialists — aligned to your program's stage and risk profile.
Featured insights
Perspectives for development and commercial leaders
Analysis across regulatory pathways, clinical evidence, and access strategy in ophthalmology.
Clinical & Scientific
Ophthalmic Gene Therapy and Next-Generation Modalities: Development Priorities for Sponsors
How sponsors should sequence indication choice, long-term follow-up, and access planning for retinal gene therapies and advanced biologics.
12 min
Regulatory
Global Regulatory Pathways for Novel Ophthalmic Therapies: FDA, EMA, and Regional Considerations
Practical guidance on agency interactions, endpoint acceptability, and harmonization for intravitreal biologics, sustained delivery, and combination products.
14 min
Clinical & Scientific
Biomarkers and Imaging in Ophthalmic Trials: Strengthening Regulatory and Payer Evidence
Translational biomarkers, OCT-based endpoints, and subgroup strategy — linking mechanism to outcomes agencies and payers will scrutinize.
11 min
Trusted partners
A curated network across the ophthalmic ecosystem
We collaborate with specialist partners across CRO delivery, imaging, translational science, regulatory execution, and commercialization.
Ophthalmic CRO partnersGlobal biopharmaEmerging biotechSpecialty pharmaAcademic research centersDiagnostics & imagingOphthalmic CRO partnersGlobal biopharmaEmerging biotechSpecialty pharmaAcademic research centersDiagnostics & imaging
Ophthalmic CRO partnersGlobal biopharmaEmerging biotechSpecialty pharmaAcademic research centersDiagnostics & imagingOphthalmic CRO partnersGlobal biopharmaEmerging biotechSpecialty pharmaAcademic research centersDiagnostics & imaging
Next steps
Discuss your ophthalmic program
Schedule a confidential consultation with our senior advisory team.